Interestingly, the suppression of glucagon by exogenous GLP-1 in type 2 diabetes was antagonised by concomitant administration of GIP, which alone did not significantly affect plasma glucagon concentrations (Fig. 4f) [41]. Here, GLP1R is linked to type 2 diabetes mellitus.